Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals in an all-cash merger. Crinetics stockholders will receive $85.00 per share in cash, implying a total equity value of approximately $10.0 billion, or about $8.8 billion net of estimated cash acquired.
At closing, Crinetics will become a wholly owned Vertex subsidiary. All unvested Crinetics stock options and restricted stock units will fully vest, with in-the-money awards converted into cash based on the $85.00 price; underwater options will be canceled. The deal is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval, antitrust and other regulatory clearances, and customary closing conditions, and is not subject to a financing condition.
Jeff Knight reports proposed dispositions of Common Stock and recent 10b5-1 sales. The filing lists 44,925 shares tied to an Exercise of Stock Options with a proposed sale date of 07/02/2026 and 2,495 Restricted Stock Units dated 03/15/2025. The excerpt also shows 10b5-1 sales totaling 120,982 shares across 04/08/2026–05/04/2026 with proceeds reported in the filing.
Crinetics Pharmaceuticals director Caren Deardorf received new equity awards in the form of restricted stock units and stock options. She was granted 5,925 restricted stock units, representing the right to receive the same number of common shares, which vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service.
She was also granted stock options covering 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. Following these awards, she directly holds 22,225 shares of common stock, in addition to the new option position.
Crinetics Pharmaceuticals director Matthew K. Fust received new equity awards as board compensation. He was granted 5,925 restricted stock units representing common shares at no purchase price, increasing his direct holdings to 28,761 common shares after the award.
Fust was also granted stock options for 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and options vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual shareholder meeting, subject to his continued board service.
Crinetics Pharmaceuticals director Nichols Weston received new equity awards. The filing shows a grant of 5,925 shares of common stock in the form of restricted stock units, bringing his direct common share holdings to 22,225. He was also granted a stock option over 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual meeting of stockholders, subject to his continued service on the board.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio received equity compensation on June 18, 2026. He was granted 5,925 shares of Common Stock in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service. He also received options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, vesting on the same schedule and expiring on June 18, 2036. Following these grants, he directly holds 22,225 Common Shares and 9,730 stock options.
Crinetics Pharmaceuticals director Camille L. Bedrosian reported receiving new equity awards. She was granted 5,925 restricted stock units representing rights to receive Common Stock, vesting 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to continued board service.
She also received stock options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. After these awards, she directly holds 22,225 shares of Common Stock and 9,730 options.
Crinetics Pharmaceuticals director Wendell Wierenga received new equity awards in the form of stock and options. He was granted 5,925 shares of Common Stock as restricted stock units at no cost, bringing his direct holdings to 122,071 shares after the grant.
He also received a stock option covering 9,730 shares of Common Stock with an exercise price of $35.87 per share and an expiration date in 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to his continued service on the board.
Crinetics Pharmaceuticals director Stephanie Okey received new equity awards as board compensation. She was granted 5,925 restricted stock units representing future common shares and a stock option for 9,730 shares at an exercise price of $35.87 per share. The restricted stock units and option vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued board service. Following the grant, she holds 12,325 shares of common stock directly.